title: Melatonin inhibits spontaneous and oxytocin-induced contractions of rat myometrium in vitro.
abstract: OBJECTIVE
  The aim of this study was to investigate the effects of melatonin on spontaneous and oxytocin-induced contractility of pregnant and non-pregnant rat myometrium in vitro.
  
  
  METHODS
  Myometrial strips were removed from virgin or late pregnant (21 days gestation) Wistar rats following decapitation and placed in an organ bath containing Krebs' solution at 37 degrees C and pH 7.4, constantly bubbled with 95% oxygen-5% carbon dioxide and isometric contractions were recorded. Effects of cumulative concentrations of melatonin (0.1 to 10 microM) on spontaneous and oxytocin-induced contractions were studied. Possible involvement of Ca(2+)-activated K (+) channels in inhibitory actions of melatonin was investigated by using apamin (100 nM).
  
  
  RESULTS
  Melatonin inhibited spontaneous and oxytocin-induced contractions of myometrium from both virgin and late pregnant rats in a dose-dependent manner. After inhibition of oxytocin-induced contractions by melatonin, application of prostaglandin F (2alpha) (1 microM) but not high KCl (30 mM) containing solution initiated contractile activity. Inhibitory response induced by melatonin (13 microM) was not affected by apamin (100 nM).
  
  
  CONCLUSIONS
  Data from this study demonstrates that melatonin inhibits spontaneous and oxytocin-induced contractions of myometrium from pregnant and non-pregnant rats. Although the exact mechanism is not clear, melatonin-induced inhibition of myometrial contractions may results from its interactions with Ca(2+) channels.
authors.affiliation: Department of Pharmacology, Firat University, Faculty of Medicine, Elazig, Turkey. aayar@firat.edu.tr
authors.forename: A
authors.initials: A
authors.lastname: Ayar
authors.forename: S
authors.initials: S
authors.lastname: Kutlu
authors.forename: B
authors.initials: B
authors.lastname: Yilmaz
authors.forename: H
authors.initials: H
authors.lastname: Kelestimur
mesh_terms: D000818:Animals; D001030:Apamin / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015237:Dinoprost / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008550:Melatonin / Q000494:pharmacology*; D010121:Oxytocin / Q000494:pharmacology*; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D011189:Potassium Chloride / Q000494:pharmacology; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D012996:Solutions; D014590:Uterine Contraction / Q000187:drug effects*
chemical_list: D016861:Cyclooxygenase Inhibitors; D015221:Potassium Channels; D012996:Solutions; D001030:Apamin; D010121:Oxytocin; D011189:Potassium Chloride; D015237:Dinoprost; D008550:Melatonin; D002118:Calcium; D007213:Indomethacin